Zachary Hornby, Boundless Bio CEO
March 21, 2024 07:03 AM EDT
Financing
Startups

Bound­less Bio seeks $88M in IPO as it runs two Ph1 can­cer tri­als

Kyle LaHucik

Senior Reporter

The spring IPO class is here.

Bound­less Bio, a can­cer biotech with two dif­fer­ent oral small mol­e­cules in Phase 1 test­ing, eyes about $88.4 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times